REQUEST A DEMO
Total
USD $0.00
Search more companies

Hanall Bio Pharma Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Hanall Bio Pharma Co.,Ltd. Profile Updated: July 04, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Hanall Biopharma Co is a company with research and development capabilities and a new drug development strategy. They offer products such as ObioPama, Probiotics 'BioTower' Santects, and Cellulites Release.

Headquarters
400-1 Sangseo-Dong, Daedeok-Gu
Daejeon; Daejeon; Postal Code: 306-120

Contact Details: Purchase the Hanall Bio Pharma Co.,Ltd. report to view the information.

Website: http://www.hanall.co.kr

Basic Information
Total Employees:
Purchase the Hanall Bio Pharma Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Hanall Bio Pharma Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Hanall Bio Pharma Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Hanall Bio Pharma Co.,Ltd. report to view the information.
Incorporation Date:
November 20, 1973
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Managing Director
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Outside Director
Ownership Details
Purchase this report to view the information.
9.2%
Purchase this report to view the information.
9.1%
Purchase this report to view the information.
4.8%
Purchase this report to view the information.
1.9%
Purchase this report to view the information.
1.5%
Subsidiaries
Daewoong Co.,Ltd. (Seongnam)
Company Performance
Financial values in the chart are available after Hanall Bio Pharma Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
29.19%
Total operating revenue
29.21%
Operating profit (EBIT)
858.28%
EBITDA
198.09%
Net Profit (Loss) for the Period
1009.38%
Total assets
29.5%
Total equity
28.34%
Operating Profit Margin (ROS)
4.76%
Net Profit Margin
5.45%
Return on Equity (ROE)
2.85%
Debt to Equity Ratio
-0.15%
Quick Ratio
-0.52%
Cash Ratio
0.45%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?